Propanc Biopharma Receives Nasdaq Minimum Bid Price Notice

Propanc Biopharma ( (PPCB) ) has issued an announcement.

On December 31, 2025, Propanc Biopharma received a notice from Nasdaq that its common stock no longer met the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market, after trading below that threshold for 35 consecutive business days. The company has until June 30, 2026, to regain compliance—either by its share price closing at or above $1.00 for at least ten consecutive business days or, if eligible, by using an additional 180-day compliance period that could include a reverse stock split—while its stock remains listed for now and business operations and SEC reporting are not immediately affected; however, potential delisting could reduce liquidity, hinder capital-raising efforts, limit access to public markets, and weaken its ability to offer equity incentives, posing significant risks to shareholders and corporate financing.

More about Propanc Biopharma

Propanc Biopharma, Inc. is a biotechnology company whose common stock is listed on the Nasdaq Capital Market, giving it access to public equity markets and a broad base of investors. The company’s listing status is important for maintaining liquidity in its shares, attracting potential shareholders and retaining the ability to raise capital through public offerings and provide equity-based incentives to employees.

Average Trading Volume: 217,947

Technical Sentiment Signal: Strong Sell

Current Market Cap: $7.24M

See more insights into PPCB stock on TipRanks’ Stock Analysis page.